GlaxoSmithKline plc Rating Reiterated by JPMorgan Chase & Co. (GSK)
GlaxoSmithKline plc (LON:GSK)‘s stock had its “neutral” rating reaffirmed by equities researchers at JPMorgan Chase & Co. in a research report issued on Tuesday. They currently have a GBX 1,700 ($28.86) target price on the stock. JPMorgan Chase & Co.’s target price points to a potential upside of 7.15% from the stock’s previous close.
Several other analysts have also recently commented on the stock. Analysts at Societe Generale raised their price target on shares of GlaxoSmithKline plc from GBX 2,075 ($35.22) to GBX 2,100 ($35.65) in a research note on Thursday, June 12th. They now have a “buy” rating on the stock. Separately, analysts at Deutsche Bank reiterated a “hold” rating on shares of GlaxoSmithKline plc in a research note on Tuesday, June 3rd. They now have a GBX 1,660 ($28.18) price target on the stock. Four investment analysts have rated the stock with a sell rating, twelve have assigned a hold rating and seven have given a buy rating to the company. The company presently has an average rating of “Hold” and an average target price of GBX 1,713.24 ($29.08).
Shares of GlaxoSmithKline plc (LON:GSK) traded down 0.56% on Tuesday, hitting GBX 1586.50. 6,491,814 shares of the company’s stock traded hands. GlaxoSmithKline plc has a one year low of GBX 1200.668 and a one year high of GBX 1762.0001. The stock has a 50-day moving average of GBX 1617. and a 200-day moving average of GBX 1615.. The company’s market cap is £76.374 billion.
GlaxoSmithKline plc (LON:GSK) is global healthcare group, which is engaged in the creation and discovery, development, manufacture and marketing of pharmaceutical products, including vaccines, over-the-counter (OTC) medicines and health-related consumer products.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.